Cancer-Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple-Negative Breast Cancer Via the Activation of Cancer-Associated Fibroblasts

Overview

Journal Glob Chall

Date 2025 Mar 12

PMID 40071217

Authors

Jingjing Fan

Tong Sha

Binlin Ma

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most prevalent cancer and a leading cause of death among women globally, posing a significant public health challenge. Triple-negative breast cancer (TNBC), an aggressive subtype accounting for 15-20% of all breast cancers, lacks targeted therapies due to the absence of hormone receptors and HER2, resulting in poor prognosis and high recurrence rates. This study investigates the role of cancer-derived extracellular vesicle (EV) integrin beta-2 (ITGB2) in TNBC progression. These findings reveal that ITGB2 is significantly overexpressed in TNBC tissues and serum EVs, correlating with advanced tumor stages and poor patient survival. ITGB2 enhances TNBC progression by activating cancer-associated fibroblasts (CAFs) within the tumor microenvironment, promoting tumor growth, migration, and invasion. Mechanistic studies demonstrate that EV ITGB2 facilitates CAF activation, driving tumor-stroma interactions that support TNBC progression. These results highlight ITGB2 as a potential biomarker and therapeutic target in TNBC, emphasizing the need for novel interventions to combat this challenging breast cancer subtype.

References

Xu H, Zhang A, Han X, Li Y, Zhang Z, Song L . ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunol Immunother. 2021; 71(3):645-660. PMC: 10992927. DOI: 10.1007/s00262-021-03022-2. View

Zhang M, Sun Q, Han Z, Qin X, Gao T, Xu Y . Construction of a novel disulfidptosis-related lncRNAs signature for prognosis prediction and anti-tumor immunity in laryngeal squamous cell carcinoma. Heliyon. 2024; 10(10):e30877. PMC: 11107247. DOI: 10.1016/j.heliyon.2024.e30877. View

Rimal R, Desai P, Daware R, Hosseinnejad A, Prakash J, Lammers T . Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. Adv Drug Deliv Rev. 2022; 189:114504. DOI: 10.1016/j.addr.2022.114504. View

Liu M, Gou L, Xia J, Wan Q, Jiang Y, Sun S . LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2. Int J Mol Sci. 2018; 19(7). PMC: 6073814. DOI: 10.3390/ijms19071866. View

Zhang H, Shi Y, Ying J, Chen Y, Guo R, Zhao X . A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021. Front Endocrinol (Lausanne). 2023; 14:1164692. PMC: 10158729. DOI: 10.3389/fendo.2023.1164692. View

Liu Y, Zhao S, Chen Y, Ma W, Lu S, He L . Vimentin promotes glioma progression and maintains glioma cell resistance to oxidative phosphorylation inhibition. Cell Oncol (Dordr). 2023; 46(6):1791-1806. DOI: 10.1007/s13402-023-00844-3. View

Anderson N, Simon M . The tumor microenvironment. Curr Biol. 2020; 30(16):R921-R925. PMC: 8194051. DOI: 10.1016/j.cub.2020.06.081. View

Desgrosellier J, Cheresh D . Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2009; 10(1):9-22. PMC: 4383089. DOI: 10.1038/nrc2748. View

Zhang M, Zhang F, Wang J, Liang Q, Zhou W, Liu J . Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo.... J Transl Med. 2024; 22(1):423. PMC: 11070106. DOI: 10.1186/s12967-024-05237-0. View

10.

Ribeiro R, Carvalho M, Goncalves J, Moreira J . Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022; 9:903065. PMC: 9437219. DOI: 10.3389/fmolb.2022.903065. View

11.

Hua S, Wang W, Yao Z, Gu J, Zhang H, Zhu J . The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma. J Cancer Res Clin Oncol. 2024; 150(2):40. PMC: 10822006. DOI: 10.1007/s00432-023-05580-7. View

12.

Li J, Wu Z, Pan Y, Chen Y, Chu J, Cong Y . GNL3L exhibits pro-tumor activities via NF-κB pathway as a poor prognostic factor in acute myeloid leukemia. J Cancer. 2024; 15(13):4072-4080. PMC: 11212074. DOI: 10.7150/jca.95339. View

13.

Jabbari N, Akbariazar E, Feqhhi M, Rahbarghazi R, Rezaie J . Breast cancer-derived exosomes: Tumor progression and therapeutic agents. J Cell Physiol. 2020; 235(10):6345-6356. DOI: 10.1002/jcp.29668. View

14.

Shapaer T, Chen Y, Pan Y, Wu Z, Tang T, Zhao Z . Elevated BEAN1 expression correlates with poor prognosis, immune evasion, and chemotherapy resistance in rectal adenocarcinoma. Discov Oncol. 2024; 15(1):446. PMC: 11401830. DOI: 10.1007/s12672-024-01321-5. View

15.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

16.

Zheng Z, Guo Y, Zheng Y, Wu H . miR-92b ameliorates lipoteichoic acid induced endometritis by suppressing Wnt/β-catenin pathway activation. Theriogenology. 2023; 214:307-313. DOI: 10.1016/j.theriogenology.2023.11.003. View

17.

Arnaout M . Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990; 75(5):1037-50. View

18.

Zhang X, Dong Y, Zhao M, Ding L, Yang X, Jing Y . ITGB2-mediated metabolic switch in CAFs promotes OSCC proliferation by oxidation of NADH in mitochondrial oxidative phosphorylation system. Theranostics. 2020; 10(26):12044-12059. PMC: 7667693. DOI: 10.7150/thno.47901. View

19.

Shayimu P, Awula M, Wang C, Jiapaer R, Pan Y, Wu Z . Serum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patients. World J Gastrointest Surg. 2024; 16(10):3142-3154. PMC: 11577407. DOI: 10.4240/wjgs.v16.i10.3142. View

20.

Wu D, Liu Y, Liu J, Ma L, Tong X . Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma. Sci Rep. 2024; 14(1):17460. PMC: 11286868. DOI: 10.1038/s41598-024-68111-5. View